Latest News and Press Releases
Want to stay updated on the latest news?
-
BONITA, CA--(Marketwired - August 17, 2015) - PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the...
-
NEW YORK, NY--(Marketwired - July 30, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is a small international biotechnology firm, but you wouldn't know it by the company it keeps. How does PharmaCyte keep...
-
BONITA, CA--(Marketwired - July 24, 2015) - A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a...
-
BONITA, CA--(Marketwired - July 21, 2015) - In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is,...
-
BONITA, CA--(Marketwired - July 13, 2015) - While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs...
-
NEW YORK, NY--(Marketwired - June 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) announced this week that the Company is able to advance its Cannabis research now that its research partner, The...
-
NEW YORK, NY--(Marketwired - June 03, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate...
-
NEW YORK, NY--(Marketwired - May 20, 2015) - PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science -- bring together an international group of leading experts to...
-
NEW YORK, NY--(Marketwired - April 23, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The...
-
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...